Quincy Bioscience receives investment
This article was originally published in The Tan Sheet
Executive Summary
A capital infusion from the investment group DaneVest Tech Fund I will help Quincy Bioscience market its "novel" dietary supplement Prevagen, the Madison, Wis.-based biotech announces Aug. 25. Quincy launched the brain cell protection supplement in 2007 and says the unquantified investment "will accelerate our goal to make Prevagen a national brand" (1"The Tan Sheet" Aug. 10, 2009). Prevagen's active ingredient apoaequorin comes from jellyfish and is a calcium-binding protein that helps buffer excess calcium from damaging aging neurons, Quincy says
You may also be interested in...
Brain Gain: Supplements And Nutraceuticals Expand Cognitive Health Science
The next generation of substances to slow cognitive decline and perhaps even prevent Alzheimer's disease may take a test run through the dietary supplement and nutraceutical markets
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.